Drug intelligence / Profile preview

umc119-06

Development stage: Phase 1
Lead developer: Meridigen Biotech
Modality: Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

UMC119-06 is an investigational cell therapy product consisting of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs), developed by Meridigen Biotech. The drug is being studied for its potential therapeutic effects including anti-oxidation, immunomodulation, lung cell protection, and anti-fibrosis. Its primary indications under investigation include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and ischemic stroke. The mechanism of action involves the replacement or supplementation of damaged or dysfunctional cells with healthy mesenchymal stem cells to promote tissue repair and modulate immune responses[1][2][4][8].

Beyond the preview

Go deeper on umc119-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on umc119-06.

Explore the full profile